Connect with us

Business

Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar

Published

on

Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar


Eli Lilly on Thursday reported third-quarter earnings and revenue that topped estimates and hiked its full-year outlook, as the company continued to see strong demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro.

Shares of the company closed more than 3% higher Thursday.

The pharmaceutical giant now expects its fiscal 2025 revenue to come in between $63 billion and $63.5 billion, up from previous guidance of $60 to $62 billion. Eli Lilly also expects full-year adjusted profit to come in between $23 and $23.70 per share, rising from its previous outlook of $21.75 to $23 a share.

Eli Lilly said the guidance reflects President Donald Trump‘s existing tariffs as of Thursday, but does not include his threatened levies on pharmaceuticals imported into the U.S.

Mounjaro raked in $6.52 billion in revenue for the quarter, up 109% from the same period a year ago. That blew past the $5.51 billion that analysts were expecting, according to StreetAccount. 

Zepbound, which entered the market roughly two years ago, posted $3.59 billion in revenue for the third quarter. That’s up 184% from the year-earlier period and slightly ahead of the $3.5 billion that Wall Street was expecting, according to StreetAccount estimates.

David Ricks, chief executive officer of Eli Lilly & Co., during a news conference at Generation Park in Houston, Texas, US, on Tuesday, Sept. 23, 2025.

Mark Felix | Bloomberg | Getty Images

In an interview with CNBC on Thursday, Eli Lilly CEO Dave Ricks said the “real star here” of the quarter is tirzepatide, the active ingredient in Zepbound and Mounjaro. Both drugs are leading the U.S. market for obesity and diabetes, he said. 

Ricks said the quarterly beat was driven by “really strong international performance,” pointing to Mounjaro’s launch in China, Brazil and India earlier this year. 

“What we’re seeing is a global demand for this product,” he told CNBC’s “Squawk on the Street.”

On an earnings call Thursday, Ricks said Eli Lilly gained share in the injectable obesity and diabetes market for the fifth consecutive quarter. The company’s drugs account for nearly 6 out of 10 prescriptions within that class of medicines.

Here’s what Eli Lilly reported for the third quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG: 

  • Earnings per share: $7.02 adjusted vs. $5.69 expected
  • Revenue: $17.60 billion vs. $16.01 billion expected

The results come as Eli Lilly works to maintain its edge over chief rival Novo Nordisk in the booming market for a class of obesity and diabetes drugs called GLP-1s.

The company posted third-quarter revenue of $17.60 billion, up 54% from the same period a year ago. 

Sales in the U.S. jumped 45% to $11.30 billion. Eli Lilly said that was driven by a 60% increase in volume — or the number of prescriptions or units sold — for its products, primarily for Mounjaro and Zepbound. That was partially offset by lower realized prices of the drugs, the company said.

The pharmaceutical giant booked net income of $5.58 billion, or $6.21 per share, for the third quarter. That compares with net income of $970.3 million, or $1.07 per share, a year earlier. 

Excluding one-time items associated with the value of intangible assets and other adjustments, Eli Lilly posted earnings of $7.02 per share for the second quarter.

The results underscore Eli Lilly’s strong advantage in the booming GLP-1 drug market.

The company has gained the majority market share over the last year, thanks to the strong profile of its weight loss and diabetes injections and a boost from its direct-to-consumer sales, among other efforts. Eli Lilly took another stride to boost access to Zepbound on Wednesday, partnering with Walmart to offer in-store pickup of discounted vials of the drug for cash-paying patients.

In the interview, Ricks said Eli Lilly plans to expand its direct-to-consumer and cash-pay offerings for its drugs.

The company is now betting on its closely watched experimental obesity pill, orforglipron, to solidify its dominance in the space, especially as Novo Nordisk and other drugmakers race to bring their own pills or next-generation injections to the market. 

“We’ve been ramping both production and planning for really a broad global rollout upon regulatory approval,” Ricks told CNBC, referring to orforglipron’s launch.

On Thursday, Novo Nordisk launched a rival bid for U.S. obesity biotech company Metsera, hijacking an offer from Pfizer as it races to catch up to Eli Lilly.

When asked about competition, Ricks said on the earnings call that “of course, everybody would like to be in our position, but we’re focused on defending it and mostly just executing the play we have.”



Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

October GST collection up 4.6% to Rs 2 Lakh-crore despite tax cuts – The Times of India

Published

on

October GST collection up 4.6% to Rs 2 Lakh-crore despite tax cuts – The Times of India


NEW DELHI: The impact of pre-GST revamp pause in sale of several products, such as automobiles and white goods, and the lower rates rolled out from Sept 22 slowed down the growth in gross GST receipts but the mop up remained close to the Rs 2 lakh crore-level, data for October showed. Official numbers released on Saturday showed GST collections in Oct for transactions in Sept totalled 1.96 lakh crore, an increase of 4.6% compared to Rs 1.87 lakh crore in October last year.This was the slowest pace of increase this fiscal. In Aug and Sept, GST collection rose 6.5% to Rs 1.86 lakh crore and at 9.1% to Rs 1.89 lakh crore. Gross domestic revenue grew 2% to Rs 1.45 lakh crore, while tax from imports rose nearly 13% to Rs 50,884 crore in October. The data showed GST refunds rose 39.6% year-on-year in Oct to Rs 26,934 crore.In Sept, GST Council had unveiled reforms to GST rate structure, which led to a sharp reduction in rates on a raft of items, bringing relief to consumers, and the latest data showed apprehensions of decline in collections have been negated.The rate cuts, effective September 22, have revived consumption demand, and experts said GST revenues for Nov are likely to show a sharp rebound.“Despite massive rate cuts effective from September 22, a slight increase in domestic GST collection is very encouraging and shows that demand is steadily increasing,” said Pratik Jain, Partner at consulting firm Price Waterhouse & Co LLP.“Consistent increase in GST refunds (domestic as well as exports) shows confidence of tax administration that GST collections would show positive trend in future as well. Next month’s data would have the full impact of GST cuts and would be keenly awaited,” added Jain.On the back of a fillip provided by a reduction in GST on 375 items, consumers had flocked to stores and car dealerships resulting in highest Navratri sales in over a decade, government officials had earlier said, citing industry data.“The GST collections, while aligning with immediate expectations, reflect a muted momentum in Sept primarily due to rate rationalisation effect in the majority part of the Sept month and the deferred consumer spending ahead of the upcoming festive season. This anticipated lag is likely to be compensated by more robust numbers in the next month, driven by seasonal buoyancy,” said Saurabh Agarwal, Tax Partner at EY India. “The impressive, high percentage growth in collections from states and UTs like Arunachal Pradesh, Nagaland, Lakshadweep and Ladakh is a tangible indicator of holistic economic development across India,” he said.





Source link

Continue Reading

Business

Urban Company Sees Rs 59.3 Crore Loss In Q2 Due To Investments In Insta Help

Published

on

Urban Company Sees Rs 59.3 Crore Loss In Q2 Due To Investments In Insta Help


New Delhi: Home services provider Urban Company on Saturday announced a net loss of Rs 59.3 crore in Q2FY26, a significant drop from a profit of Rs 6.9 crore in the previous quarter. The loss was attributed to heavy upfront investments in its new daily-housekeeping vertical, Insta Help, which overshadowed strong revenue growth in its core services and products businesses, according to regulatory filings by the Gurugram-based firm.

The company posted a loss of Rs 1.82 crore in the July-September quarter last year, the company said. While revenue from operations increased 37 per cent year-on-year to Rs 380 crore, the total expenses rose to Rs 462 crore from Rs 384 crore in Q1. This resulted in adjusted EBITDA turning negative at Rs 35 crore, compared with a profit of Rs 21 crore in Q1.

Insta Help reported an EBITDA loss of Rs 44 crore, and excluding this segment, Urban Company achieved an adjusted EBITDA profit of Rs 10 crore, accounting for 0.9 per cent of net transaction value (NTV), the company noted.

Add Zee News as a Preferred Source


“Early indicators for Insta Help are encouraging, with strong consumer adoption and repeat usage,” the company said in its shareholder letter. It added that it believed the segment holds “significant long-term opportunity and believes these investments are important to sustaining market leadership.”

The company expects its adjusted EBITDA losses to continue in the near term due to further investments in the Insta Help vertical, despite its core India and international businesses remaining profitable and cash-generating.

The company’s smart home products vertical, Native, which sells water purifiers and electronic door locks, recorded revenue of Rs 75 crore, up 179 per cent YoY, while losses narrowed to 9 per cent of NTV from 30 per cent in the previous year.

The home services provider closed the quarter with Rs 2,136 crore in cash and equivalents, up from Rs 1,664 crore in the previous quarter, mainly due to proceeds from its recent IPO.



Source link

Continue Reading

Business

Andy Jassy Reveals Real Reason Behind Amazon 14,000 Job Cuts — And It’s Not AI

Published

on

Andy Jassy Reveals Real Reason Behind Amazon 14,000 Job Cuts — And It’s Not AI


New Delhi: Amazon CEO Andy Jassy has opened up about the company’s recent layoffs, which affected around 14,000 employees. Contrary to popular belief, he said the decision wasn’t about cutting costs or the rise of artificial intelligence. Instead, Jassy pointed to a deeper reason behind the move — company culture. “The announcement that we made a few days ago was not really financially driven, and it’s not even really AI-driven, not right now at least,” he said, as quoted by Business Insider. “It really — it’s culture.”

A Cultural Reset at Amazon

Andy Jassy’s comments reflect Amazon’s ongoing push to reshape its internal culture. As reported by Business Insider, he has been focused on raising performance standards, tightening discipline, and cutting down on unnecessary bureaucracy to make the company more efficient and agile.

Add Zee News as a Preferred Source


During the earnings call, Jassy acknowledged that Amazon’s rapid expansion over the years had added “a lot more layers,” which ended up slowing down how decisions are made. He emphasised that the company now needs to “operate leaner and move faster,” particularly as artificial intelligence continues to reshape industries worldwide.

“Sometimes, without realizing it, you can weaken the ownership of the people that you have who are doing the actual work,” Jassy said. “And it can lead to slowing you down.” In a blog post on October 28, Amazon’s senior vice president of people experience and technology, Beth Galetti, also confirmed that the company is “making organizational changes across Amazon that will impact some of our teammates.”

“While this will include reducing in some areas and hiring in others, it will mean an overall reduction in our corporate workforce of approximately 14,000 roles,” she said. This marks Amazon’s largest round of layoffs since 2022, when about 27,000 employees were let go. Interestingly, Jassy’s recent comments contrast with what other Amazon executives have previously said about the reasons behind the job cuts.

The decision also reflects a broader trend across Big Tech. Giants like Google and Microsoft are undergoing what many call the “Great Flattening” — cutting down layers of management to speed up decision-making and eliminate unnecessary bureaucracy.



Source link

Continue Reading

Trending